Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/S1517-83822013000400002 http://hdl.handle.net/11449/110081 |
Resumo: | The discovery of secondary metabolites produced by microorganisms (e.g., penicillin in 1928) and the beginning of their industrial application (1940) opened new doors to what has been the main medication source for the treatment of infectious diseases and tumors. In fact, approximately 80 years after the discovery of the first antibiotic compound, and despite all of the warnings about the failure of the goose that laid the golden egg, the potential of this wealth is still inexorable: simply adjust the focus from micro to nano, that means changing the look from microorganisms to nanograms of DNA. Then, the search for new drugs, driven by genetic engineering combined with metagenomic strategies, shows us a way to bypass the barriers imposed by methodologies limited to isolation and culturing. However, we are far from solving the problem of supplying new molecules that are effective against the plasticity of multi- or pan-drug-resistant pathogens. Although the first advances in genetic engineering date back to 1990, there is still a lack of high-throughput methods to speed up the screening of new genes and design new molecules by recombination of pathways. In addition, it is necessary an increase in the variety of heterologous hosts and improvements throughout the full drug discovery pipeline. Among numerous studies focused on this subject, those on polyketide antibiotics stand out for the large technical-scientific efforts that established novel solutions for the transfer/engineering of major metabolic pathways using transposons and other episomes, overcoming one of the main methodological constraints for the heterologous expression of major pathways. In silico prediction analysis of three-dimensional enzymatic structures and advances in sequencing technologies have expanded access to the metabolic potential of microorganisms. |
id |
UNSP_f04d7def3fcec5473e6113c36e88a8d6 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/110081 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomicsenvironmental samplespharmacologyPKSsnew drugsThe discovery of secondary metabolites produced by microorganisms (e.g., penicillin in 1928) and the beginning of their industrial application (1940) opened new doors to what has been the main medication source for the treatment of infectious diseases and tumors. In fact, approximately 80 years after the discovery of the first antibiotic compound, and despite all of the warnings about the failure of the goose that laid the golden egg, the potential of this wealth is still inexorable: simply adjust the focus from micro to nano, that means changing the look from microorganisms to nanograms of DNA. Then, the search for new drugs, driven by genetic engineering combined with metagenomic strategies, shows us a way to bypass the barriers imposed by methodologies limited to isolation and culturing. However, we are far from solving the problem of supplying new molecules that are effective against the plasticity of multi- or pan-drug-resistant pathogens. Although the first advances in genetic engineering date back to 1990, there is still a lack of high-throughput methods to speed up the screening of new genes and design new molecules by recombination of pathways. In addition, it is necessary an increase in the variety of heterologous hosts and improvements throughout the full drug discovery pipeline. Among numerous studies focused on this subject, those on polyketide antibiotics stand out for the large technical-scientific efforts that established novel solutions for the transfer/engineering of major metabolic pathways using transposons and other episomes, overcoming one of the main methodological constraints for the heterologous expression of major pathways. In silico prediction analysis of three-dimensional enzymatic structures and advances in sequencing technologies have expanded access to the metabolic potential of microorganisms.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Graduate Program on Microbiologia Agropecuaria from UNESP-FCAVUniversidade Estadual Paulista Júlio de Mesquita Filho Faculdade de Ciências Agrárias e Veterinárias Departamento de TecnologiaUniversidade Estadual Paulista Júlio de Mesquita Filho Faculdade de Ciências Agrárias e Veterinárias Departamento de TecnologiaSociedade Brasileira de MicrobiologiaUniversidade Estadual Paulista (Unesp)Gomes, Elisângela Soares [UNESP]Schuch, Viviane [UNESP]Lemos, Eliana Gertrudes De Macedo [UNESP]2014-10-01T13:08:48Z2014-10-01T13:08:48Z2013-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1007-1034application/pdfhttp://dx.doi.org/10.1590/S1517-83822013000400002Brazilian Journal of Microbiology. Sociedade Brasileira de Microbiologia, v. 44, n. 4, p. 1007-1034, 2013.1517-8382http://hdl.handle.net/11449/11008110.1590/S1517-83822013000400002S1517-83822013000400002WOS:000333959600002S1517-83822013000400002.pdf39020209364809430000-0002-1119-7748[3]SciELOreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBrazilian Journal of Microbiology1.8100,630info:eu-repo/semantics/openAccess2024-06-07T15:31:47Zoai:repositorio.unesp.br:11449/110081Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T17:43:14.089488Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
title |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
spellingShingle |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics Gomes, Elisângela Soares [UNESP] environmental samples pharmacology PKSs new drugs |
title_short |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
title_full |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
title_fullStr |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
title_full_unstemmed |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
title_sort |
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics |
author |
Gomes, Elisângela Soares [UNESP] |
author_facet |
Gomes, Elisângela Soares [UNESP] Schuch, Viviane [UNESP] Lemos, Eliana Gertrudes De Macedo [UNESP] |
author_role |
author |
author2 |
Schuch, Viviane [UNESP] Lemos, Eliana Gertrudes De Macedo [UNESP] |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Gomes, Elisângela Soares [UNESP] Schuch, Viviane [UNESP] Lemos, Eliana Gertrudes De Macedo [UNESP] |
dc.subject.por.fl_str_mv |
environmental samples pharmacology PKSs new drugs |
topic |
environmental samples pharmacology PKSs new drugs |
description |
The discovery of secondary metabolites produced by microorganisms (e.g., penicillin in 1928) and the beginning of their industrial application (1940) opened new doors to what has been the main medication source for the treatment of infectious diseases and tumors. In fact, approximately 80 years after the discovery of the first antibiotic compound, and despite all of the warnings about the failure of the goose that laid the golden egg, the potential of this wealth is still inexorable: simply adjust the focus from micro to nano, that means changing the look from microorganisms to nanograms of DNA. Then, the search for new drugs, driven by genetic engineering combined with metagenomic strategies, shows us a way to bypass the barriers imposed by methodologies limited to isolation and culturing. However, we are far from solving the problem of supplying new molecules that are effective against the plasticity of multi- or pan-drug-resistant pathogens. Although the first advances in genetic engineering date back to 1990, there is still a lack of high-throughput methods to speed up the screening of new genes and design new molecules by recombination of pathways. In addition, it is necessary an increase in the variety of heterologous hosts and improvements throughout the full drug discovery pipeline. Among numerous studies focused on this subject, those on polyketide antibiotics stand out for the large technical-scientific efforts that established novel solutions for the transfer/engineering of major metabolic pathways using transposons and other episomes, overcoming one of the main methodological constraints for the heterologous expression of major pathways. In silico prediction analysis of three-dimensional enzymatic structures and advances in sequencing technologies have expanded access to the metabolic potential of microorganisms. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-12-01 2014-10-01T13:08:48Z 2014-10-01T13:08:48Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S1517-83822013000400002 Brazilian Journal of Microbiology. Sociedade Brasileira de Microbiologia, v. 44, n. 4, p. 1007-1034, 2013. 1517-8382 http://hdl.handle.net/11449/110081 10.1590/S1517-83822013000400002 S1517-83822013000400002 WOS:000333959600002 S1517-83822013000400002.pdf 3902020936480943 0000-0002-1119-7748[3] |
url |
http://dx.doi.org/10.1590/S1517-83822013000400002 http://hdl.handle.net/11449/110081 |
identifier_str_mv |
Brazilian Journal of Microbiology. Sociedade Brasileira de Microbiologia, v. 44, n. 4, p. 1007-1034, 2013. 1517-8382 10.1590/S1517-83822013000400002 S1517-83822013000400002 WOS:000333959600002 S1517-83822013000400002.pdf 3902020936480943 0000-0002-1119-7748[3] |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Brazilian Journal of Microbiology 1.810 0,630 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1007-1034 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Microbiologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Microbiologia |
dc.source.none.fl_str_mv |
SciELO reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128849639112704 |